{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:26:47Z","timestamp":1790717207349,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,3]]},"DOI":"10.7759\/cureus.81663","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T20:24:17Z","timestamp":1743711857000},"source":"Crossref","is-referenced-by-count":5,"title":["From Prescription to Predicament: A Case of Semaglutide-Induced Discoid Lupus Erythematosus in an Adult Male Patient"],"prefix":"10.7759","author":[{"given":"Kristina","family":"Nazzicone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"O'Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000344","article-title":"Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program","volume":"6","author":"Izmirly P","year":"2019","unstructured":"Izmirly P, Buyon J, Belmont HM, et al.. Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. Lupus Sci Med. 2019, 6:e000344. 10.1136\/lupus-2019-000344","journal-title":"Lupus Sci Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304070-00002","article-title":"Cutaneous lupus erythematosus: diagnosis and management","volume":"4","author":"Fabbri P","year":"2003","unstructured":"Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003, 4:449-65. 10.2165\/00128071-200304070-00002","journal-title":"Am J Clin Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002954.pub3","article-title":"Drugs for discoid lupus erythematosus","volume":"5","author":"Jessop S","year":"2017","unstructured":"Jessop S, Whitelaw DA, Grainge MJ, Jayasekera P. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2017, 5:CD002954. 10.1002\/14651858.CD002954.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000522","article-title":"Drug-induced lupus erythematosus: an update on drugs and mechanisms","volume":"30","author":"He Y","year":"2018","unstructured":"He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018, 30:490-7. 10.1097\/BOR.0000000000000522","journal-title":"Curr Opin Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317691369","article-title":"Trigger factors of cutaneous lupus erythematosus: a review of current literature","volume":"26","author":"Szcz\u0119ch J","year":"2017","unstructured":"Szcz\u0119ch J, Samotij D, Werth VP, Reich A. Trigger factors of cutaneous lupus erythematosus: a review of current literature. Lupus. 2017, 26:791-807. 10.1177\/0961203317691369","journal-title":"Lupus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2025.103186","article-title":"Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases","volume":"19","author":"Sun Y","year":"2025","unstructured":"Sun Y, Zhou Q, Onzere LE, et al.. Evaluating the causal effect of using glucagon-like peptide-1 receptor agonists on the risk of autoimmune diseases. Diabetes Metab Syndr. 2025, 19:103186. 10.1016\/j.dsx.2025.103186","journal-title":"Diabetes Metab Syndr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0706-2","article-title":"Pathophysiology of cutaneous lupus erythematosus","volume":"17","author":"Achtman JC","year":"2015","unstructured":"Achtman JC, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther. 2015, 17:182. 10.1186\/s13075-015-0706-2","journal-title":"Arthritis Res Ther"},{"key":"ref9","unstructured":"Drug-induced lupus erythematosus. (2020). Accessed. October 28, 2024: https:\/\/emedicine.medscape.com\/article\/1065086-overview."},{"key":"ref10","article-title":"Discoid Lupus Erythematosus","author":"McDaniel B","year":"2025","unstructured":"McDaniel B, Sukumaran S, Koritala T, Tanner LS. Discoid Lupus Erythematosus. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2025."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-02969-3","article-title":"Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature","volume":"316","author":"Salazar CE","year":"2024","unstructured":"Salazar CE, Patil MK, Aihie O, Cruz N, Nambudiri VE. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Arch Dermatol Res. 2024, 316:248. 10.1007\/s00403-024-02969-3","journal-title":"Arch Dermatol Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02466-4","article-title":"Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network: author list","volume":"48","author":"Nassar M","year":"2025","unstructured":"Nassar M, Nassar O, Abosheaishaa H, Misra A. Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network: author list. J Endocrinol Invest. 2025, 48:483-97. 10.1007\/s40618-024-02466-4","journal-title":"J Endocrinol Invest"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan AE","year":"2011","unstructured":"Hogan AE, Tobin AM, Ahern T, et al.. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011, 54:2745-54. 10.1007\/s00125-011-2232-3","journal-title":"Diabetologia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1698290","article-title":"Cutaneous lupus erythematosus induced by drugs - novel insights","volume":"13","author":"Borucki R","year":"2020","unstructured":"Borucki R, Werth VP. Cutaneous lupus erythematosus induced by drugs - novel insights. Expert Rev Clin Pharmacol. 2020, 13:35-42. 10.1080\/17512433.2020.1698290","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.55324","article-title":"Semaglutide-induced lupus erythematosus with multiorgan involvement","volume":"16","author":"Castellanos V","year":"2024","unstructured":"Castellanos V, Workneh H, Malik A, Mehta B. Semaglutide-induced lupus erythematosus with multiorgan involvement. Cureus. 2024, 16:e55324. 10.7759\/cureus.55324","journal-title":"Cureus"},{"key":"ref16","unstructured":"Canada Vigilance Adverse Reaction Online Database. (2019). Accessed. October 28, 2024: https:\/\/cvp-pcv.hc-sc.gc.ca\/arq-rei\/."},{"key":"ref17","unstructured":"FDA Adverse Events Reporting System (FAERS) public dashboard. (2024). Accessed. October 28, 2024: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/a...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/312980-from-prescription-to-predicament-a-case-of-semaglutide-induced-discoid-lupus-erythematosus-in-an-adult-male-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T20:24:27Z","timestamp":1743711867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/312980-from-prescription-to-predicament-a-case-of-semaglutide-induced-discoid-lupus-erythematosus-in-an-adult-male-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.81663","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,3]]}}}